Key facts
- This page summarizes Trafford Clarke's Form 4 filing for Traws Pharma, Inc. (TRAW).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Dec 2025, 18:22.
Trafford Clarke - 12 Dec 2025 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)
- Reporting relationship
- Director
- Issuer ticker
- TRAW
- Reported as of
- 12 Dec 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Dec 2025, 18:22:44 UTC
- Prior SEC filing
- 15 Oct 2025
- Next SEC filing
- 10 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Trafford Clarke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Trafford Clarke filed Form 4 for Traws Pharma, Inc. (TRAW) on 16 Dec 2025.
Change
- Previous filing in this sequence was filed on 15 Oct 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001958857
Primary reporting owner
Clarke Trafford
- Relationship
- Director
- Address
- C/O TRAWS PHARMA, INC., 12 PENNS TRAIL, NEWTOWN
- Signature
- /s/ Trafford Clarke
- Signature date
- 16 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRAW
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,157
- Change %
- Price
- $0.000000
- Shares after
- 6,157
- Date
- 12 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRAW
transaction
Derivative
Stock Option (right to purchase)
Award
- Transaction value
- $0
- Shares
- +24,629
- Change %
- Price
- $0.000000
- Shares after
- 24,629
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,629
- Exercise price
- $2.33
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.
Footnote F2
The options vest 100% on the first anniversary of the grant date.